Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic
  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

FDA approves Novo Nordisk's Rivfloza therapy for rare kidney condition

On Monday, Novo Nordisk announced that its therapy for treating a rare genetic kidney condition has received approval from the U.S. Food and Drug Administration.

Novo Nordisk said on Monday the U.S. Food and Drug Administration (FDA) had approved its therapy to treat a rare genetic condition that affects the kidneys.

The once-monthly injection, which will be sold under the brand name Rivfloza, is approved for use in children who are 9 years of age and older and adults with a type of primary hyperoxaluria and relatively preserved kidney function.

OZEMPIC DIABETES AND WEIGHT LOSS MEDICATION UNDER INVESTIGATION AFTER A FEW REPORTS OF SUICIDAL THOUGHTS

Primary hyperoxaluria is a rare condition characterized by recurrent kidney and bladder stones.

The Danish drugmaker gained access to the therapy through its $3.3 billion buyout of Dicerna Pharmaceuticals.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.